Technology
Health
Biotechnology
Veracyte
$30.939876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$30.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.08 (3.62%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours
Why Robinhood?
You can buy or sell Veracyte and other stocks, options, ETFs, and crypto commission-free!
About VCYT
Veracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. Read More It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
CEO
—
Employees
270
Headquarters
South San Francisco, California
Founded
2008
Market Cap
1.24B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
485.97K
High Today
$31.16
Low Today
$29.84
Open Price
$29.84
Volume
789.22K
52 Week High
$31.16
52 Week Low
$8.77
Collections
Technology
Health
Biotechnology
Cancer Prevention
2013 IPO
US
North America
Price Paid on Robinhood
29% Higher
Right Now
52 Week Low
$8.77
Average Price Paid
$23.88
52 Week High
$31.16
VCYT Earnings
-$0.27
-$0.20
-$0.12
-$0.05
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Available Jul 30, After Hours